Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2016
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the quarter ended September 30, 2016. This filing serves as Regulation FD disclosure, noting that the Tanshin is substantially the same as the Company's Form 10-Q for the same period, with the addition of a full-year forecast.
Key Financial Metrics
The filing provides a financial results forecast for the full year ending December 31, 2016. Specific historical financial metrics for the quarter ended September 30, 2016 (revenue, profit, cash flow, margins, debt, and liquidity) are not detailed in this text, as the document references the Form 10-Q for those figures.
| Forecast Metric (Full Year 2016) | Value |
|---|---|
| Revenues | $0 |
| Operating Loss | $10,254,000 |
| Net Loss | $10,254,000 |
| Expected Basic and Diluted Loss Per Share | $0.31 |
Note: The loss per share calculation uses a weighted average of 33,400,000 shares. Supplementary financial statements in Japanese yen were translated at a rate of 101.12 yen per U.S. dollar.
Material Changes
The filing does not explicitly detail material changes in financial performance compared to the prior comparable period. It states that the Tanshin is substantially the same as the Form 10-Q for the quarter ended September 30, 2016, except for the inclusion of the full-year forecast and supplementary yen-denominated statements.
Guidance, Outlook, and Risks
Guidance: Management forecasts a full-year 2016 net loss of $10,254,000 with zero revenue. The filing explicitly states that these estimates are based on management's assumptions and are not audited by independent auditors.
Risks and Uncertainties: The Company cautions that actual results may differ materially from estimates due to factors beyond its control. Key risks include:
- Regulatory approval timelines and outcomes for product candidates.
- Delays in clinical trial enrollment or completion.
- Adverse side effects or inadequate therapeutic efficacy.
- Challenges in manufacturing, marketing, and obtaining regulatory approval.
- Intellectual property validity and scope.
- Ability to raise sufficient capital or debt financing.
- Market competition and economic conditions.
The Company disclaims any obligation to update these forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the detailed historical financial results for the quarter ended September 30, 2016, in the referenced Form 10-Q, as they are not included in this 8-K.
- Confirm the weighted average share count of 33,400,000 used for the loss per share calculation.
- Review the Form 10-K for the year ended December 31, 2015, for detailed risk factors referenced in the forecast disclaimer.
- Monitor the Company's ability to raise capital given the projected full-year net loss and zero revenue.
- Track the progress of clinical trials and regulatory submissions for product candidates, as these are primary drivers of future financial performance.